Advanced Oncotherapy Stock

Advanced Oncotherapy ROE 2024

Advanced Oncotherapy ROE

-0.48

Ticker

AVO.L

ISIN

GB00BD6SX109

WKN

A2AL9X

In 2024, Advanced Oncotherapy's return on equity (ROE) was -0.48, a 0% increase from the 0 ROE in the previous year.

Advanced Oncotherapy Aktienanalyse

What does Advanced Oncotherapy do?

Advanced Oncotherapy PLC is a therapeutic company in London specializing in the development of advanced and precise radiation therapy solutions. The company was founded in 2005 and has since developed a revolutionary technology that allows for the treatment of cancer cells with the highest precision and minimal to no damage to surrounding tissue. The business model of Advanced Oncotherapy aims to offer innovative technology solutions that benefit patients throughout their medical cancer treatment. The various facets of the company include research and development, production, sales and distribution, as well as clinical trials. Advanced Oncotherapy focuses on a direct customer-customer relationship by offering customers interesting treatment options tailored to the patient's needs. The flagship product of Advanced Oncotherapy is the LIGHT radiation therapy system, which is unique worldwide due to its precision, accuracy, and effectiveness in the treatment of cancer. This system allows oncologists and radiologists to perform innovative radiation therapy that promises better treatment outcomes. The LIGHT technology is based on the principles of intensity-modulated radiation therapy (IMRT) and next-generation particle therapy (NGPT). By using proton beams, the radiation therapy can be focused directly on a specific region of the body where cancer tissue is spreading. Advanced Oncotherapy offers a wide range of radiation therapy services to its customers. This includes proton accelerators (PROTON), PET/CT systems (positron emission tomography/computed tomography), CT scanners (computed tomography), and other tools and devices. The product line has been specifically developed for the precise irradiation of tumors as well as the diagnosis of cancer and other related diseases. Customers of Advanced Oncotherapy are primarily hospitals, medical centers, and health authorities. In recent years, Advanced Oncotherapy has collaborated closely with various partners such as CERN (European Organization for Nuclear Research), the Royal Marsden Hospital, University College London, and other institutions to constantly improve and further develop its technology and products. Milestones in the company's history include the CE marking for the LIGHT system and support for clinical trials by research-intensive university hospitals. The future of Advanced Oncotherapy looks promising, with a strong growth forecast for the global radiation therapy market. With an increasing demand for innovative solutions in cancer treatment, the company can look forward to a growing customer base and an increasing number of partnerships and collaborations. Advanced Oncotherapy will continue to focus on continuously optimizing its technology to provide cancer patients with the best treatment options. Advanced Oncotherapy ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Advanced Oncotherapy's Return on Equity (ROE)

Advanced Oncotherapy's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Advanced Oncotherapy's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Advanced Oncotherapy's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Advanced Oncotherapy’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Advanced Oncotherapy stock

What is the ROE (Return on Equity) of Advanced Oncotherapy this year?

The ROE of Advanced Oncotherapy this year is -0.48 undefined.

How has the Return on Equity (ROE) of Advanced Oncotherapy developed compared to the previous year?

The ROE of Advanced Oncotherapy has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Advanced Oncotherapy?

A high ROE indicates that Advanced Oncotherapy generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Advanced Oncotherapy?

A low ROE can indicate that Advanced Oncotherapy is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Advanced Oncotherapy affect the company?

A change in ROE (Return on Equity) of Advanced Oncotherapy can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Advanced Oncotherapy?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Advanced Oncotherapy?

Some factors that can influence Advanced Oncotherapy's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Advanced Oncotherapy pay?

Over the past 12 months, Advanced Oncotherapy paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Advanced Oncotherapy is expected to pay a dividend of 0 GBP.

What is the dividend yield of Advanced Oncotherapy?

The current dividend yield of Advanced Oncotherapy is .

When does Advanced Oncotherapy pay dividends?

Advanced Oncotherapy pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Advanced Oncotherapy?

Advanced Oncotherapy paid dividends every year for the past 0 years.

What is the dividend of Advanced Oncotherapy?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Advanced Oncotherapy located?

Advanced Oncotherapy is assigned to the 'Health' sector.

Wann musste ich die Aktien von Advanced Oncotherapy kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Advanced Oncotherapy from 11/9/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Advanced Oncotherapy pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Advanced Oncotherapy in the year 2023?

In the year 2023, Advanced Oncotherapy distributed 0 GBP as dividends.

In which currency does Advanced Oncotherapy pay out the dividend?

The dividends of Advanced Oncotherapy are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Advanced Oncotherapy

Our stock analysis for Advanced Oncotherapy Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Advanced Oncotherapy Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.